XML 46 R30.htm IDEA: XBRL DOCUMENT
v3.25.1

Segment Reporting (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment | The following table reconciles reported revenues to net loss under the significant expense principle for the three months ended March 31, 2025 and 2024:
| Three Months Ended March 31,
| 2025 |  | 2024
Revenues | $ | 8,720 |  |  | $ | 12,053 |
Costs and expenses: |  |  |
Total Manufacture and Supply Expenses | 3,652 |  |  | 4,389 |
R&D Project expenses: |  |  |
Anaphylm project expenses | 2,488 |  |  | 3,147 |
AQST-108 project expenses | 195 |  |  | 789 |
Libervant project expenses | — |  |  | 17 |
R&D other expenses: |  |  |
Personnel costs 1 | 2,132 |  |  | 1,704 |
Other 2 | 546 |  |  | 275 |
Total Research and Development Expenses | 5,361 |  |  | 5,932 |
Selling expenses: |  |  |
Personnel costs 3 | 694 |  |  | 932 |
Other 4 | 2,262 |  |  | 140 |
Total Selling expenses | 2,956 |  |  | 1,072 |
General & Administrative expenses: |  |  |
Personnel costs 5 | 4,840 |  |  | 4,661 |
Other 6 | 11,276 |  |  | 4,956 |
Total General and Administrative Expenses | 16,116 |  |  | 9,617 |
Total Selling, General and Administrative Expenses | 19,072 |  |  | 10,689 |
Total costs and expenses | 28,085 |  |  | 21,010 |
Loss from operations | (19,365) |  |  | (8,957) |
Other expenses | (3,565) |  |  | (3,871) |
Net loss before income taxes | (22,930) |  |  | (12,828) |
Net loss | $ | (22,930) |  |  | $ | (12,828) |
Comprehensive loss | $ | (22,930) |  |  | $ | (12,828) |
1 - R&D Personnel costs include payroll expenses, share-based compensation expenses and severance
2 - Other Research and Development expenses include preclinical, consulting, maintenance, and testing fees
3 - Selling Personnel costs include payroll expenses and severance
4 - Other Selling expenses include commercialization and other related expenses
5 - G&A Personnel costs include payroll expenses, share-based compensation expenses and severance
6 - Other General and Administrative expenses include legal/patent fees, insurance fees, IT expenses, investor relations expenses, regulatory fees, facility and other costs

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration